Centrus Energy Corp.
Two segments: (1) LEU — sells separative work units (SWU) and uranium to commercial utilities, today largely sourced via a Russian TENEX supply contract resold into the US/EU, transitioning to own US centrifuge production; (2) Technical Solutions — cost-plus / fixed-fee government contracts, principally the DOE HALEU Operation Contract at Piketon. Revenue is contract/backlog-driven with heavy commodity-price (SWU) leverage and large, financing-gated capex to scale domestic enrichment.
The thesis on this name
State of Nuclear Energy
The single highest-leverage way to play U.S. fuel-cycle reshoring. Enrichment (SWU) is the bottleneck every SMR fuel order and every Russian-LEU-replacement contract must pass through, and Centrus is the only domestic public pure-play. 2026 revenue guide raised to $450-500M, Q1'26 net income $10M, $900M DOE task order de-risking the HALEU buildout. Not pre-revenue — a real ramp on a national-security tailwind.
State of Nuclear Energy
The highest-conviction asymmetric single name: the West's only public HALEU + LEU enricher sitting on the fuel-cycle chokepoint, with a $900M DOE HALEU task order and a 2026 revenue ramp.
State of Nuclear Energy
The West's only public HALEU + LEU enricher and the single highest-leverage way to play U.S. fuel-supply-chain reshoring. Jan-2026 $900M DOE HALEU task order (+ up to $170M options), funded $108M HALEU operation option year, 2026 revenue guide raised to $450-500M, $1.87B cash. Enrichment (SWU) is the chokepoint that every SMR and every Russian-replacement LEU contract has to pass through. Sized below the ETF/anchor core only because it has run hard (~$163, ~$3.4B mcap) and is execution/appropriations-dependent.
Earnings, margins, COGS & capex
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~74¢ is cost of goods and ~25¢ operating expense, leaving ~1¢ of operating profit.
Revenue trend
Margins
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-02-11. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
Centrus is the only US-owned, US-technology enrichment company with a licensed, operating HALEU cascade — the single most de-risked seat in the US fuel-reshoring trade, now backed by a $900M DOE award, a $3.8B backlog and a ~$2B cash war chest to fund expansion.
- Monopoly-adjacent strategic position: the only US-owned/US-tech HALEU producer with an NRC-licensed, operating AC-100M cascade at Piketon (operational 2023); delivered >1 MT HALEU UF6 and a 900 kg milestone to DOE. HALEU is the fuel bottleneck for nearly every US advanced reactor / SMR (TerraPower, X-energy, Oklo, Kairos, Radiant).
- Government tailwind is direct and large: $900M competitively-awarded DOE task order (Jan 2026) to build commercial-scale HALEU at Piketon, plus up to $170M of HALEU-delivery options and a $108.2M funded option year on the HALEU Operation Contract — part of the DOE's $2.7B reshoring program explicitly aimed at ending reliance on Russian enrichment.
- Balance sheet to actually build: FY2025 cash of ~$2.0B (net cash ~$690M after $1.17B converts) gives funded runway for the first phase of expansion without immediate equity dilution at depressed prices.
- Backlog visibility: $3.8B total backlog through 2040, including ~$2.3B of contingent LEU sales commitments ($2.1B under definitive agreements) and ~$0.9B Technical Solutions — multi-year revenue scaffolding rare for a sub-$500M-revenue company.
- Profitable today, unlike SMR/fusion peers: FY2025 net income $77.8M, diluted EPS $3.90, positive gross profit in both segments — a real cash-generative LEU book funding the HALEU option, not a pre-revenue story.
- Optionality stacking: Oklo deconversion JV at Piketon (Mar 2026) co-locates enrichment + deconversion next to Oklo's planned 1.2 GW campus; KHNP/POSCO investment talks and an AI-datacenter-power narrative add demand pull and potential non-dilutive expansion capital.
Today's profits depend heavily on reselling cheap Russian TENEX LEU — a contract that is being banned/curtailed and is the very thing Centrus is supposed to replace; the US-production future requires multi-billion-dollar capex, definitive-contract conversion, and SWU prices staying high, none guaranteed, against three larger, better-capitalized Western enrichers.
- Russia paradox at the core of margins: a large share of LEU-segment economics has come from importing Russian TENEX LEU and reselling it at a spread. Moscow already cancelled TENEX's US export license once (stock -10%), and the US Russian-uranium import ban phases this out — the cash cow and the strategic mission are in direct conflict, and replacement supply is years and billions away.
- SWU price leverage cuts both ways: Q3'25 saw SWU average price down ~69% YoY on some volumes and a $24.1M SWU revenue hit; if Russian supply returns or Urenco/Orano overcapacity lands sooner, SWU prices soften and 'contingent' backlog may not convert. Q1'26 already showed margin compression (net income $10.0M vs $27.2M YoY).
- The $900M award and most of the backlog are conditional: the commercial-scale HALEU task order is 'subject to negotiation of a definitive agreement,' and $0.2B of LEU backlog plus the contingent commitments depend on securing 'substantial public and private investment' — execution-, permitting-, and financing-gated, not contracted cash.
- Capex wall and dilution risk: a multi-billion-dollar Piketon expansion dwarfs the ~$690M net cash; the company is already running negative FCF and has a $1B ATM plus $1.1B of converts (strike ~$229.62 on the 2032s) — future equity/conversion dilution is a live risk if private capital and offtake don't fully fund the build.
- Stiff, larger competition: Urenco (adding 2.5M SWU by 2030, USA cascade live), Orano (also a $900M DOE awardee, building a US enrichment plant), and well-funded newcomer General Matter ($900M award) all chase the same US enrichment demand; Centrus is not a guaranteed share-winner despite first-mover HALEU status.
- Concentration + valuation: heavy customer concentration (DOE + a few utilities), ~$3.25B market cap on ~$450-500M revenue (~7x sales) for a thin-margin, capex-heavy enricher, and a stock down ~37% YTD / off a $464 high signal the easy multiple-expansion phase is over and the next leg is execution-dependent.
What it is worth
Sum-of-the-parts / scenario framing on a profitable enricher with a large optioned expansion, cross-checked vs EV/sales and net cash. FY2025 rev $448.7M, net income $77.8M (EPS $3.90); ~22.4M diluted shares; ~$3.25B market cap; EV ≈ market cap − ~$690M net cash ≈ ~$2.56B → EV/sales ~5.7x, P/E ~42x trailing.
~$70-110/share
Russian-supply curtailment compresses LEU margins before US production replaces them, SWU prices soften on Western overcapacity, the $900M/contingent backlog slips or needs heavy dilution ($1B ATM + convert dilution at $229.62), and the multiple de-rates to a mid-single-digit P/E on a thinner, capex-burdened earnings base.
~$160-200/share
Capitalizes the existing LEU + Technical Solutions book at ~25-30x earnings (premium for strategic scarcity + backlog) and adds modest, risk-adjusted credit for HALEU commercialization — roughly today's ~$164-172 price, i.e. fairly valued for delivery on the current plan.
~$300-450/share
Piketon expansion is fully funded (DOE definitive agreements + KHNP/POSCO non-dilutive capital), SWU prices hold, contingent LEU backlog converts, and Centrus captures outsized US HALEU share as advanced reactors deploy — re-rating toward a strategic-monopoly multiple (revisiting prior highs as earnings scale into the backlog).
Highly scenario-dependent: the spread between bull and bear is driven by (1) whether expansion is funded without major dilution, (2) SWU-price direction, and (3) conditional-backlog conversion. A real method (SOTP + EV/sales + net-cash floor) anchors the range, but execution and commodity leverage make point estimates low-confidence — hence medium conviction. Not financial advice.
SWOT
Strengths
- Only US-owned, US-technology HALEU producer with a licensed, operating AC-100M centrifuge cascade (Piketon, OH).
- Profitable and cash-generative LEU trading book funding the HALEU build (FY2025 net income $77.8M, EPS $3.90).
- ~$2.0B cash / ~$690M net cash and a $3.8B multi-year backlog through 2040.
- Direct DOE backing ($900M task order, $108.2M funded option, NNSA sole-source intent) — policy-aligned with US fuel reshoring.
Weaknesses
- Legacy LEU margins still depend on reselling Russian TENEX material that is being banned — the cash cow contradicts the mission.
- Thin/volatile operating margins; high SWU-price sensitivity (Q3'25 SWU price -69% on some volumes).
- Negative free cash flow and a large pending capex bill vs. a modest revenue base.
- Heavy customer concentration (DOE + a small group of utilities).
Opportunities
- HALEU supply bottleneck for the entire US advanced-reactor/SMR fleet (TerraPower, X-energy, Oklo, Kairos, Radiant, Westinghouse).
- Commercial-scale HALEU + additional LEU production at Piketon under DOE program; up to $170M delivery options.
- Oklo deconversion JV and AI-datacenter nuclear demand as new offtake and co-investment channels.
- Non-dilutive expansion capital from KHNP/POSCO and other strategic/government sources.
Threats
- Return of Russian enrichment or faster Western overcapacity (Urenco +2.5M SWU by 2030; Orano US plant) compressing SWU prices.
- Conditional awards/backlog failing to convert to definitive contracts or to secure required private investment.
- Dilution from the $1B ATM and conversion of $1.1B of convertible notes.
- Permitting, construction-cost, and execution risk on a first-of-kind multi-billion-dollar US enrichment expansion.
Moats, dependencies & bottlenecks
Moats
US-technology HALEU enrichment capability (licensed AC-100M cascade, operating since 2023) Regulatory + technology + first-mover moat; durable for now but Orano/General Matter/Urenco are building competing US capacity with equal government backing.
$900M award, NNSA sole-source intent) Hard for new entrants to replicate the incumbent operating contract, but awards are competitive and conditional, not exclusive.
capital-intensive enrichment infrastructure High barriers to entry (licensing, security, classified centrifuge tech) protect the few who clear them.
$3.8B through 2040 gives scaffolding, but the largest contingent slices are investment-dependent.
Dependencies
Largest customer and the source of the $900M award + HALEU Operation Contract; a policy or appropriations shift would hit revenue and the expansion thesis directly.
Historical margin source being curtailed by the US import ban and Moscow's export-license actions — both a dependency and the risk it creates.
LEU-segment economics swing with SWU pricing; a softening (Russian return / Western overcapacity) compresses margins and threatens contingent backlog conversion.
Multi-billion-dollar Piketon build exceeds net cash; depends on DOE definitive agreements, KHNP/POSCO, and capital markets — dilution risk via $1B ATM and $1.1B converts.
HALEU commercial demand is gated by when TerraPower, X-energy, Oklo, Kairos, etc. actually deploy at scale.
Bottlenecks
- Capital: the gap between ~$690M net cash and a multi-billion-dollar Piketon expansion is the binding constraint — financing it without heavy dilution is the central execution challenge.
- Definitive-contract conversion — the $900M commercial-scale task order and ~$2.3B contingent LEU commitments must convert from conditional to definitive agreements to be bankable.
- Supply transition — replacing curtailed Russian TENEX LEU with domestic centrifuge output before margins and delivery commitments are impaired.
- HALEU demand timing — advanced-reactor deployment must arrive on schedule to absorb commercial-scale HALEU capacity built ahead of revenue.
- Centrifuge manufacturing scale-up — ramping domestic AC-series production (Oak Ridge) and trained operators fast enough to hit the post-2030 12 MT/yr HALEU target.
Top signals & trends
Top signals
Direct federal capital + demand validation for the only US-tech HALEU producer.
Government-contract momentum; Technical Solutions HALEU revenue +47% YoY in Q1'26.
Multi-decade visibility, but the contingent portion depends on securing public/private investment.
Mix shift and SWU-price pressure are eroding near-term profitability even as revenue grows.
De-rating from euphoric highs; sentiment still positive but multiple has reset to ~7x sales.
The legacy profit engine is being switched off before US production can fully replace it.
Co-location with Oklo's 1.2 GW campus targets the HALEU deconversion bottleneck.
Funding gap implies future dilution unless private/government capital fully bridges the build.
Trends
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Russian LEU supplied under the TENEX Supply Contract — historical source of resale-spread margin, now being phased out by US ban / export-license cancellation.
Major uranium (U3O8/feed) supplier; feedstock and conversion (Port Hope) for the fuel cycle.
US UF6 conversion (Metropolis, IL) — conversion step feeding enrichment.
Centrus's own domestic AC-series centrifuge manufacturing launched Dec 2025 — vertically integrated supply input.
Largest customer — HALEU Operation Contract, the $900M task order, and HALEU offtake; also funder of the reshoring program.
Planned deconversion JV at Piketon co-located with Oklo's 1.2 GW campus; prospective HALEU offtake for Aurora microreactors.
Natrium reactor developer; DOE-conditional HALEU recipient — core advanced-reactor HALEU demand. Private (Gates-backed).
Xe-100 SMR + TRISO-X fuel; DOE HALEU recipient and a key future enrichment buyer. Private.
~$2.3B contingent LEU commitments from domestic + export utilities for the existing reactor fleet.
World's largest Western enricher (UK/DE/NL consortium); Urenco USA (NM) cascade live, adding 2.5M SWU by 2030. The dominant SWU competitor; not US-listed.
French state-controlled enricher; also a $900M DOE HALEU/LEU awardee (Jan 2026) building US enrichment. Direct head-to-head for US reshoring share. Private/state-owned.
Well-funded US enrichment startup; $900M DOE award alongside Centrus. Pre-production but capitalized and policy-favored. Private.
Laser-enrichment JV (Silex Systems + Cameco-backed); $28M DOE award. Different tech path (SILEX); earlier-stage but disruptive if it scales.
Quantum-enrichment HALEU developer; signed a TerraPower term sheet for a HALEU facility — competes for the same advanced-reactor offtake.
Russian state enricher controlling ~44% of global capacity; simultaneously Centrus's largest historical LEU supplier and the strategic adversary US policy aims to displace. State-owned.
China's state enricher — significant global capacity; analysis-only, not an investable comp and never a buy/own recommendation.